4//SEC Filing
MEDGENICS, INC. 4
Accession 0001144204-14-001695
CIK 0001138776operating
Filed
Jan 9, 7:00 PM ET
Accepted
Jan 10, 5:30 PM ET
Size
20.2 KB
Accession
0001144204-14-001695
Insider Transaction Report
Form 4
MEDGENICS, INC.MDGN
Pearlman Andrew
President and CEO
Transactions
- Exercise/Conversion
Common Stock
2014-01-09$2.49/sh+28,466$70,880→ 69,028 total - Exercise/Conversion
Common Stock
2014-01-09$3.14/sh+6,000$18,840→ 75,028 total - Sale
Common Stock
2014-01-09$6.69/sh−34,466$230,578→ 40,562 total - Exercise/Conversion
Common Stock
2014-01-08$2.49/sh+45,534$113,380→ 86,096 total - Exercise/Conversion
Option Award
2014-01-09−6,000→ 74,000 totalExercise: $3.14Exp: 2021-12-09→ Common Stock (6,000 underlying) - Sale
Common Stock
2014-01-08$6.54/sh−45,534$297,792→ 40,562 total - Exercise/Conversion
Option Award
2014-01-09−28,466→ 108,806 totalExercise: $2.49Exp: 2014-09-13→ Common Stock (28,466 underlying) - Exercise/Conversion
Option Award
2014-01-08−45,534→ 137,272 totalExercise: $2.49Exp: 2014-09-13→ Common Stock (45,534 underlying)
Holdings
- 1,719(indirect: By LLC)
Common Stock
- 94(indirect: By Spouse)
Common Stock
Footnotes (6)
- [F1]The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2013.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.47 to $6.82, inclusive. The reporting person undertakes to provide Medgenics, Inc., any security holder of Medgenics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.50 to $6.75, inclusive. The reporting person undertakes to provide Medgenics, Inc., any security holder of Medgenics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The option award became exercisable in four equal annual installments beginning on March 31, 2007, which was the first anniversary of the grant date.
- [F5]The expiration date of these options was previously reported as March 31, 2016.
- [F6]The option award becomes exercisable in four equal annual installments beginning on December 9, 2012, which was the first anniversary of the grant date.
Documents
Issuer
MEDGENICS, INC.
CIK 0001138776
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001138776
Filing Metadata
- Form type
- 4
- Filed
- Jan 9, 7:00 PM ET
- Accepted
- Jan 10, 5:30 PM ET
- Size
- 20.2 KB